STAT+: GSK drug’s new approval sets up competition with Dupixent
And more biotech news brought to you by The Readout.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Apologies that this newsletter is coming late to you this morning — we had some technical difficulties. But we’ve still got the news for you today.GLP-1
Novo’s marketing push with telehealth sparks concern
As pharma companies try to get more compounded GLP-1 users on branded versions of the drugs, they’re embracing certain telehealth providers as marketing partners.